Nonsteroidal topical treatments for atopic dermatitis have gained prominence, reducing reliance on steroids and their associated side effects.
PDE4 inhibitors block phosphodiesterase 4, decreasing pro-inflammatory cytokine production and mitigating inflammation in atopic dermatitis.
The evolution of nonsteroidal options reflects a broader trend towards targeted therapies in dermatology, offering improved safety profiles and efficacy.
SHOW MORE
Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.
Can you provide an overview of the current landscape of topical treatments for atopic dermatitis and how these options, specifically nonsteroidal options, have evolved over the past decade?
What is the mechanism of action of PDE4 inhibitors, and how do they specifically target the inflammatory pathways in atopic dermatitis?